Tag: Phase III Trial
Viaskin Peanut Completes Phase III Part A Study of Toddlers With...
Part B expected to commence in 2018Q4 with Viaskin Peanut 250 µg.
Aimmune to Submit FDA Application for Peanut OIT Candidate by End...
If approved, AR101 could be offered as the first FDA approved OIT therapy for peanut allergy.
Results of Phase III Trial of Aimmune’s Peanut OIT Therapy
After one year, 3/4 of patients ages 4-17 who received the therapy were able to consume a minimum of 300mg of peanut. Results for adults were less clear.
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Positive Safety Results Reported for Viaskin Peanut Phase III Trial
The trial met its primary objective, demonstrating that Viaskin Peanut was well-tolerated with no new or unexpected adverse events.
Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA...
The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Aimmune Begins Patient Enrollment for Phase III Clinical Trial of Peanut...
First of 440 patients enrolled in study of AR101.
Peanut Patch Phase III Enrollment Ends, Results Expected Toward End of...
The study received higher-than-expected patient demand.
